Despite significant additions to our armamentarium of antiepileptic drugs (AEDs), considerable numbers of patients with epilepsy are medically intractable. Seizure control is attained in 47% of patients with the initial AED. If ineffective, subsequent trials of monotherapy or polytherapy will attain seizure control in only 67%. 1 Surgery may be an option for some with focal onset, yet many will be left taking multiple AEDs in an attempt to control their seizures. Polypharmacy is associated with increased side effects, 2 and medically intractable patients suffer significant morbidity and mortality from continued 
associated with increased side effects, 2 and medically intractable patients suffer significant morbidity and mortality from continued seizures. The first human vagus nerve stimulation (VNS) implantation occurred in 1988, and US Food and Drug Administration (FDA) approval for adjunctive seizure therapy in patients aged 12 or older was obtained in July 1997. VNS has become an invaluable tool in the treatment of refractory epilepsy. It is cost-effective [3] [4] [5] [6] and has been shown to reduce the number of hospitalisations in some groups. 7 Treatment of refractory depression became the second indication for VNS in 2005. Implantation is generally an outpatient procedure in which a generator is placed subcutaneously in the left anterior chest and paired leads are placed around the left vagus nerve within the carotid sheath. In this paper, we briefly review the proposed mechanisms of action of VNS, as well as the efficacy and safety of VNS in medically intractable epilepsy in adults and children.
Proposed Mechanisms of Vagus Nerve Stimulation
The mechanism by which VNS exerts its effect has not been fully elucidated. However, several studies have shed light on possible mechanisms of VNS action (for recent reviews see references 8 and 9).
Vagus nerve afferents are made up of three fibre types:
1. large-diameter, myelinated A-fibres; 2. intermediate-diameter, myelinated B-fibres; and 3. small-diameter, unmyelinated C-fibres.
Destruction of C-fibres does not attenuate the antiseizure response to VNS 10 and electrophysiological studies indicate that typical VNS parameters do not activate C-fibres. 11 Thus, A and B-fibres likely mediate VNS responses.
Vagus afferent fibres innervate several medullary structures, with the nucleus of the tractus solitarius (NTS) receiving bilateral inputs totalling 80% of all vagal afferents. NTS has widespread projections, including direct or multiple synaptic projections to the parabrachial nucleus, vermis, inferior cerebellar hemispheres, raphe nuclei, periaquaductal grey, locus coeruleus, thalamus, hypothalamus, amygdala, nucleus accumbens, anterior insula, infralimbic cortex and lateral pre-frontal cortex, making delineation of the area mediating VNS effects difficult. NTS output has been shown to be important in modulating susceptibility to seizure in rats. 12 Blocking function of the locus coeruleus attenuates the antiseizure effect of VNS in rodents. 13 and parietal lobules -but was absent from other areas. 16, 17 Intriguingly, thalamic blood flow response to VNS in the acute phase predicted the likelihood of clinical response to chronic, intermittent VNS. 16, 17 Previous PET studies also had shown increased thalamic blood flow in response to VNS. 18 
Shocking the Wandering Nerve -Vagus Nerve Stimulation
After a Decade of Widespread Use shown decreased thalamic activity in response to VNS. 22 In summary,
contradictory observations make it difficult to draw definitive conclusions; however, thalamic involvement remains a likely candidate underlying VNS efficacy.
Vagus Nerve Stimulation Efficacy in Adults and Children
The first large, randomised, blinded study of VNS in humans (EO3) was patients were evaluated, and the high-frequency group had a statistically significant reduction in seizure frequency of 27.9% compared with 15.2% in the low-frequency group (see Figure 1 ). An open extension study re-evaluated patients at 12 months, and seizure frequency was reduced by 45%. 28 In a compassionate-use, multicentre, prospective, open-label trial (EO4) of 24 patients with medically resistant generalised epilepsy aged 4-40 years, 29 there was an overall reduction in seizure frequency of 46%, with 45 .8% of patients demonstrating a greater than 50% reduction in seizure frequency, clearly demonstrating a benefit for generalised seizures, similar to other studies. 30, 31 Several other studies have confirmed the efficacy of VNS. 7, [32] [33] [34] [35] Compiled long-term data from EO1-EO5 36 demonstrated that 23% of patients had a greater than 50% reduction in seizure frequency at three months, and that this increased to 37% at one year, 43% at year two and then plateaued, staying at 43% at year three, suggesting improved effect over time. This trend was also shown in a registry study in which patients had stable dosing of AED over 12 months, demonstrating that 45% of patients had greater than 50% reduction in seizures at three months, increasing to 58% at 12 months. 37 Additionally, VNS may allow some patients to reduce the number or dose of AEDs taken, 38, 39 though with non-responders, 17.8% of patients had increased numbers of AEDs. 39 Although the initial trials for VNS included patients as young as 12 years old, it was not until later that trials separated paediatric data or designed purely paediatric trials. Murphy et al. 40 compiled the data on children from the two blinded, randomised trials 25, 27 (two children from EO3, 17 children from EO5) combined with 41 patients enrolled in a compassionate-use protocol that included patients with partial seizures, primary generalised seizures or secondary generalised seizures, for a total of 60 patients. The mean age was 13.5 years, with the youngest recipient aged 3.5 years and 16 children under 12 years of age. Pooled data indicated a mean reduction in seizure frequency of 22% at three months, increasing to 42% at 18 months. No significant difference was seen in children less than 12 years old, and no single seizure type appeared more responsive to VNS therapy. 40 The largest paediatric study to date was a retrospective, multicentre evaluation of 125 patients with medically intractable epilepsy. 41 Follow-up data at three months were available in 95 patients and demonstrated an average reduction of seizure frequency of 36.1%, with a median reduction of 51.5%. Furthermore, 28.4% of patients had a greater than 75% reduction in seizure frequency, and two patients became seizure-free. Data were available from 56 patients at six months, with reduction in seizure frequency of 44.7% and median reduction of 51%. A greater than 50% reduction was seen in 57% of patients, and 30% showed a greater than 75% seizure reduction. No significant difference was found in patients under 12 years of age.
Other studies have shown similar results. 42 Fifty children with Lennox-Gastaut syndrome (LGS) were evaluated in a multicentre retrospective study. One month following VNS there was a 42% reduction in seizure frequency, including 43% of patients with a greater than 50% reduction in seizure frequency. At six months, seizure reduction was 57.9%, with 58% of patients showing a decrease of The most common side effects reported in clinical trials are hoarseness, voice change or cough associated with stimulation. The rate of hoarseness or voice alteration in the first two randomised, blinded trials was 37.2-66.3% at three months, and coughing in 7.5-45.3% at three months. 25, 27 Importantly, there are no significant cognitive side effects.
Compiled data from clinical trials EO1-EO5 looked at side effects at 12-36 months (see Figure 2) . By 12 months only 29% experienced hoarseness and 7.8% had cough, indicating possible attenuation of side effects with time. 36 Ben-Menachem looked at patients as far out as five years, and hoarseness was reported in 11 out of 64 patients. 31 Other commonly reported side effects include dyspnoea, paresthaesias and pain at surgical site. 25, 27, 29, 31, 36 Similar side effects have been found in paediatric populations. 3, [40] [41] [42] [43] [44] 46 Conclusions VNS has been shown to be efficacious and safe for the treatment of 
